Abbott has received CE-marking for its Architect Stat High-Sensitive troponin I assay. The test measures very low levels of cardiac troponin, which allows physicians to evaluate, in two to four hours, whether patients are having a heart attack.
The Architect Stat High-Sensitive troponin I chemiluminescent microparticle immunoassay is for the quantitative determination of cardiac troponin I (cTnI) in human plasma and serum on the company’s Architect i system with stat protocol capability.
The assay runs on Abbott’s automated Architect family of analyzers and is available in CE-marked and nonregulated countries, pending country registration.
Abbott, 847-937-6100